Ni J, et al. - Researchers assessed the expression of C-type lectin domain family 3 member A (CLEC3A) and its clinical relevance in breast invasive ductal cancer (IDC) and its impact on breast cancer (BC) cell proliferation and metastasis. They analyzed the level of CLEC3A expression in The Cancer Genome Atlas (TCGA) datasets. Using the Kaplan–Meier method and Cox’s proportional-hazards model, overall survival (OS) analysis was carried out. A possible correlation between elevated CLEC3A expression and breast IDC metastatic potential was suggested. In breast IDC, elevated CLEC3A expression was identified as an indicator of poor prognosis. Possibly via suppressing phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling activity, CLEC3A knockdown inhibited BC cell growth and metastasis. Overall, CLEC3A holds promise as a potential therapeutic target for BC.